Obstructive Sleep Apnea in Pulmonary Arterial Hypertension (OSA in PAH)
| Status: | Recruiting |
|---|---|
| Conditions: | High Blood Pressure (Hypertension), Insomnia Sleep Studies, Pulmonary |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/5/2014 |
| Start Date: | April 2013 |
Effect of Pulmonary Arterial Hypertension Treatment on Obstructive Sleep Apnea
The purpose of this study is to determine whether pulmonary arterial hypertension can worsen
or even cause sleep apnea. It is hypothesized that if pulmonary arterial hypertension does
indeed worsen or cause sleep apnea, then the treatment should first focus on the underlying
pulmonary arterial hypertension instead of the sleep apnea.
To determine if a person has sleep apnea, they will undergo one overnight polysomnogram
(sleep study). If it is found that they have mild to moderate sleep apnea, then the subject
will be invited to continue in the study and their pulmonary arterial hypertension will be
treated by their managing primary physician. After the subject has had treatment for their
pulmonary arterial hypertension, the study center will have them return for a follow up
sleep study to learn the effects of pulmonary arterial hypertension treatment management on
their sleep apnea, 12-24 weeks after the first sleep study.
or even cause sleep apnea. It is hypothesized that if pulmonary arterial hypertension does
indeed worsen or cause sleep apnea, then the treatment should first focus on the underlying
pulmonary arterial hypertension instead of the sleep apnea.
To determine if a person has sleep apnea, they will undergo one overnight polysomnogram
(sleep study). If it is found that they have mild to moderate sleep apnea, then the subject
will be invited to continue in the study and their pulmonary arterial hypertension will be
treated by their managing primary physician. After the subject has had treatment for their
pulmonary arterial hypertension, the study center will have them return for a follow up
sleep study to learn the effects of pulmonary arterial hypertension treatment management on
their sleep apnea, 12-24 weeks after the first sleep study.
Pulmonary Arterial Hypertension (PAH) is associated with fluid retention. Currently, the
treatment paradigm for newly diagnosed PAH patients includes evaluation for Obstructive
Sleep Apnea (OSA). The investigators propose that untreated or sub-optimally managed PAH
patients have significant fluid retention which redistributes to the upper body during sleep
and exacerbates or even mimics OSA. The investigators hypothesize that treatment of PAH
patients with vasodilators and diuretics to optimize fluid balance will attenuate or even
resolve OSA prior to the initiation of specific therapy for OSA (CPAP).
treatment paradigm for newly diagnosed PAH patients includes evaluation for Obstructive
Sleep Apnea (OSA). The investigators propose that untreated or sub-optimally managed PAH
patients have significant fluid retention which redistributes to the upper body during sleep
and exacerbates or even mimics OSA. The investigators hypothesize that treatment of PAH
patients with vasodilators and diuretics to optimize fluid balance will attenuate or even
resolve OSA prior to the initiation of specific therapy for OSA (CPAP).
Inclusion Criteria:
- • Diagnosis of Group 1 PAH
- Either lack of treatment for PAH or sub-optimally treated PAH as defined by NYHA
FC 3 or 4
- Age 18 or older
- Ability to give consent
- Ability to undergo overnight polysomnogram
- Previously diagnosed OSA not on therapy
Exclusion Criteria:
- Age younger than 18
- Pregnancy
- Previously diagnosed OSA and receiving therapy
- Inability to undergo overnight polysomnography in laboratory
We found this trial at
1
site
Click here to add this to my saved trials
